Nuran Bese

Nuran Bese

Auto-generated profile, based on publicly available information

Nuran Bese

Acıbadem Research Institute of Senology, Acıbadem Mehmet Ali Aydınlar University, İstanbul, Türkiye

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
FSFatih Selcukbiricik
Fatih Selcukbiricik
DTDeniz Tural
Deniz Tural
FAFatih Aydoğan
Fatih Aydoğan
NBNuran Beşe
Nuran Beşe
EBEvin Büyükünal
Evin Büyükünal
SSSüheyla Serdengeçti
Süheyla Serdengeçti
Selcukbiricik F, et al. J Breast Cancer. 2013 Mar;16(1):60-65. http://dx.doi.org/10.4048/jbc.2013.16.1.60

1 January 2024 in European Journal of Breast Health
Verified
Journal Article
Closed access
VDVolkan Niyazi Demircan
Volkan Niyazi Demircan
NBNuran Bese
Nuran Bese
Breast cancer stands as the most prevalent malignancy, necessitating a well-established approach to its management due to its sustained prevalence over decades. The implementation of intensive treatments, combining various modalities, has yielded excellent survival outcomes. Consequently, the optimization of quality of life and the mitigation of long-term side effects emerge as critical considerations for clinicians. As a result, discussions regarding treatment de-intensification strategies have been initiated for all treatment modalities, including surgery, radiotherapy (RT), and chemotherapy. RT plays a crucial role in adjuvant therapy. The efficacy of RT in disease control and overall survival across all stages of breast cancer has been demonstrated in numerous clinical trials and meta-analyses utilizing extensive datasets. However, advancements in genetic tumor profiling and improved identification of disease subgroups have prompted a reevaluation of RT omission in low-risk groups as a strategy for treatment de-intensification. Conversely, technological improvements and shortened total treatment times with hypofractionation make RT a secure and feasible option for enhancing local control and survival with minimal impact on the quality of life.

29 August 2012 in ISRN Oncology
Verified
Journal Article
Open access
PDF file
FSFatih Selçukbiricik
Fatih Selçukbiricik
DTDeniz Tural
Deniz Tural
OEOlgun Elicin
Olgun Elicin
SBSelin Berk
Selin Berk
MÖMUSTAFA ÖZGÜROĞLU
MUSTAFA ÖZGÜROĞLU
BFBurhan Ferhanoglu
Burhan Ferhanoglu
Objectives. The aim of this study was to evaluate clinical characteristics, prognostic factors, survival rates, and treatment modalities in patients with primary gastric lymphoma (PGL). Methods. We retrospectively reviewed and analyzed data from patients treated for PGL in our clinic from 1998 through 2010. Staging was performed using the Lugano Staging System. Overall and disease-free survival (OS and DFS) were calculated from the date of diagnosis. Results. We identified 79 patients. Thirty-seven patients (47%) were male. The median age at presentation was 57 (18–85) years. The median follow-up time was 41 (9–52) months. Thirty patients (38%) underwent surgery, 74 (92%) received chemotherapy, and 18 (23%) received radiotherapy. The five-year OS and DFS rates were 91.2% and 83.9%, respectively, in patients with stage I/II or IIE disease and 70.6% and 65.5%, respectively, in patients with stage IV disease ( for both rates). Treatment modality (surgical or conservative) had no impact on OS or DFS in early stages. In a multivariate analysis, poor performance status, advanced stage, and high LDH levels were significant bad prognostic factors for DFS, while advanced stage, poor performance status, and age > 60 years were significant bad prognostic factors for OS. Conclusion. Surgery provides no advantage for survival over conservative treatment; thus, conservative treatment modalities should be preferred initially at early stages of PGL.

1 August 2022 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
EAErman Aytaç
Erman Aytaç
LOLeyla ÖzEr
Leyla ÖzEr
BBBilgi Baca
Bilgi Baca
EBEmre BALIK
Emre BALIK
YKYersu Kapran
Yersu Kapran
TKTayfun KarahasanoğlU
Tayfun KarahasanoğlU
Colorectal cancer is the third most common cancer in Turkey. The current guidelines do not provide sufficient information to cover all aspects of the management of rectal cancer. Although treatment has been standardized in terms of the basic principles of neoadjuvant, surgical, and adjuvant therapy, uncertainties in the management of rectal cancer may lead to significant differences in clinical practice. In order to clarify these uncertainties, a consensus program was constructed with the participation of the physicians from the Acıbadem Mehmet Ali Aydınlar and Koç Universities. This program included the physicians from the departments of general surgery, gastroenterology, pathology, radiology, nuclear medicine, medical oncology, radiation oncology, and medical genetics. The gray zones in the management of rectal cancer were determined by reviewing the evidence-based data and current guidelines before the meeting. Topics to be discussed consisted of diagnosis, staging, surgical treatment for the primary disease, use of neoadjuvant and adjuvant treatment, management of recurrent disease, screening, follow-up, and genetic counseling. All those topics were discussed under supervision of a presenter and a chair with active participation of related physicians. The consensus text was structured by centralizing the decisions based on the existing data. Cite this article as: Aytaç E, Özer L, Baca B, et al. Optimizing the personalized care for the management of rectal cancer: A consensus statement. Turk J Gastroenterol. 2022;33(8):627-663.

1 April 2021 in European Journal of Breast Health
Verified
Journal Article
Closed access
PAPelin Altınok
Pelin Altınok
LKLatif Korkmaz
Latif Korkmaz
AAAyse Altınok
Ayse Altınok
NBNuran Beşe
Nuran Beşe
In this study, we aimed to review the heart and left coronary artery doses over the years in patients who received breast cancer radiotherapy (RT). A total of 436 breast cancer patients of 2 RT centers treated between the years 2010 and 2018 were included. The mean heart doses (HeartDmean-HDM) and left coronary artery mean doses (LDM) were analyzed using nonparametric tests. The conventional RT (CRT) was 50 Gy/2 Gy in 5 weeks, and the hypofractionated RT (HRT) was 40.05 Gy/2.67 Gy in 3 weeks. Boost was applied as 10–16 Gy/2 Gy for CRT and 10 Gy/2.5 Gy for HRT. An equivalent conventional total dose of 2 Gy/fraction (EQD2) was taken into account for HRT. HDM was 107±104 cGy, and LDM was 288±209 cGy for the entire group. HDM was significantly lower in patients with breast-conserving surgery (99±94 cGy) than that in those with mastectomy (128±124 cGy) (p<0.001). Field-in-field intensity-modulated RT technique significantly reduced the doses compared to volumetric applications (104±95 cGy vs 141±38 cGy; p = 0.002). HDM was significantly increased with lymphatic RT (132±58 cGy vs 112±115 cGy; p<0.001). The addition of internal mammary volumes significantly increased HDM (p<0.001). No significant effect of boost was observed (p = 0.96). For both CRT and HRT regimens, HDM values were significantly lower after the year 2014 (right side p<0.001, left side p = 0.01). In the left side CRT, HDM was 1.74 Gy before 2014 and 1.3 Gy after 2014 and 1.0 and 1.19 Gy, respectively, for the right side. All efforts to reduce the cardiac doses will likely reduce long-term side effects.

1 January 2018 in Contemporary Oncology
Verified
Journal Article
Open access
PDF file
AAAyse Y. Altinok
Ayse Y. Altinok
NBNuran Bese
Nuran Bese
HKHalil KARA
Halil KARA
SYSukru Yazar
Sukru Yazar
CUCihan Unal
Cihan Unal
Aim of the study Postmastectomy reconstructive surgery for cosmetic satisfaction of patients is rapidly increasing. Postoperative complications such as infection, capsular contracture, implant loss are more common in patients who receive adjuvant radiotherapy (RT) than those who do not....